Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anaphylaxis, Dose-Ranging Hurdles May Trip Teva's Reslizumab

This article was originally published in Scrip

Executive Summary

Even though GlaxoSmithKline PLC's recently approved Nucala (mepolizumab) – the first anti-interleukin-5 (IL-5) treatment in the US for adults and adolescents with severe asthma with an eosinophilic phenotype – has paved the way for Teva Pharmaceutical Industries Ltd.'s reslizumab, when the latter drug goes before an advisory committee later this week, it must clear its own hurdles, which includes anaphylaxis and muscle toxicity, along with limited dose-ranging data, which may trip up the experimental medicine in the end.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC063902

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel